Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

201985 citationsJournal Articlegreen Open Access

Authors

Tomáš Kalinčík · The Royal Melbourne Hospital

Eva Havrdová · Charles University

Dana Horáková · Charles University

Guillermo Izquierdo · Hospital Universitario Virgen Macarena

Alexandre Prat · Hôpital Notre-Dame

Marc Girard · Hôpital Notre-Dame

Pierre Duquette ·

Abstract

The effect of fingolimod on relapse frequency was superior to teriflunomide and dimethyl fumarate. The effect of the three oral therapies on disability outcomes was similar during the initial 2.5 years on treatment. Persistence on fingolimod was superior to the two comparator drugs.

Topics & Keywords

Multiple Sclerosis Research Studies Autoimmune and Inflammatory Disorders Research Sphingolipid Metabolism and Signaling

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Neurology Neurosurgery & Psychiatry

Volume 90, Issue 4, pp. 458-468

DOI: 10.1136/jnnp-2018-319831

Field-Weighted Citation Impact: 8.61